camcevi
accord healthcare s.l.u. - leuprorelin mesilate - prostata-neoplasmen - endokrine therapie - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
cabazitaxel teva 10 mg/ml konzentrat zur herstellung einer infusionslösung
teva b.v. - cabazitaxel 2-propanol -
cabazitaxel stada 20 mg/ml konzentrat zur herstellung einer infusionslösung
stada arzneimittel ag - cabazitaxel -
locametz
novartis europharm limited - gozetotide - radionuklid-bildgebung - diagnostische radiopharmaka - dieses arzneimittel ist nur für diagnostische zwecke bestimmt. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.
akeega
janssen-cilag international n.v. - abiraterone acetate, niraparib tosilate monohydrate - prostatahyperplasie neubildungen, kastration-resistentem - antineoplastische mittel - treatment of adult patients with prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostata-neoplasmen - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
dutasterid/tamsulosin hexal 0,5 mg/0,4 mg hartkapseln
h e x a l aktiengesellschaft (3079284) - tamsulosinhydrochlorid; dutasterid - hartkapsel - teil 2 - wirkstoffhaltige pellets; tamsulosinhydrochlorid (23010) 0,4 milligramm; teil 3 - weichkapsel; dutasterid (30527) 0,5 milligramm
casodex 150 mg - filmtabletten
laboratoires juvise pharmaceuticals sas - bicalutamid - bicalutamid
finasterid-ratiopharm 5 mg - filmtabletten
teva b.v. - finasterid - finasterid
finasterid actavis 5 mg filmtabletten
actavis group ptc ehf - finasterid - finasterid